IP Library › Granted Patent US 12,466,880
Granted Patent B2
US 12,466,880 · App. 18/360,143 · Granted Nov 11, 2025

Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of glaucoma

Inventors: Bongcheol Kim (Seongnam-si, KR); Dong Sik Kim (Seoul, KR); Soon-gu Kwon (Seoul, KR)
Assignee: Neuracle Science Co., Ltd.
C07K16/24A61K48/00A61K48/0058C07K2317/565C07K2317/622C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,466,880
App. No.
18/360,143
Granted
Nov 11, 2025
Kind
B2
Abstract

The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a glaucoma in a subject in need thereof.

Claims (38)

1 . A method for treating a glaucoma in a subject in need thereof comprising administering to the subject a polynucleotide encoding an antibody, or an antigen binding portion thereof, that specifically binds to a family with sequence similarity 19, member A5 (FAM19A5) protein (anti-FAM19A5 antibody), wherein the anti-FAM19A5 antibody comprises a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3, and wherein:

(i) the heavy chain CDR1, CDR2, and CDR3 comprises the amino acid sequence set forth in SEQ ID NOs: 11, 12, and 13, respectively, and the light chain CDR1, CDR2, and CDR3 comprises the amino acid sequence set forth in SEQ ID NOs: 23, 24, and 25, respectively;

(ii) the heavy chain CDR1, CDR2, and CDR3 comprises the amino acid sequences set forth in SEQ ID NOs: 14, 15, and 16, respectively, and the light chain CDR1, CDR2, and CDR3 comprises the amino acid sequences set forth in SEQ ID NOs: 26, 27, and 28, respectively;

(iii) the heavy chain CDR1, CDR2, and CDR3 comprises the amino acid sequences set forth in SEQ ID NOs: 17, 18, and 19, respectively, and the light chain CDR1, CDR2, and CDR3 comprises the amino acid sequences set forth in SEQ ID NOs: 29, 30, and 31, respectively; or

(iv) the heavy chain CDR1, CDR2, and CDR3 comprises the amino acid sequences set forth in SEQ ID NOs: 20, 21, and 22, respectively, and the light chain CDR1, CDR2, and CDR3 comprises the amino acid sequences set forth in SEQ ID NOs: 32, 33, and 34, respectively.

2 . A method for reducing, ameliorating, or inhibiting inflammation associated with a glaucoma in a subject in need thereof comprising administering to the subject a polynucleotide encoding an antibody, or an antigen binding portion thereof, that specifically binds to a family with sequence similarity 19, member A5 (FAM19A5) protein (anti-FAM19A5 antibody), wherein the anti-FAM19A5 antibody comprises a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3, and wherein:

(i) the heavy chain CDR1, CDR2, and CDR3 comprises the amino acid sequence set forth in SEQ ID NOs: 11, 12, and 13, respectively, and the light chain CDR1, CDR2, and CDR3 comprises the amino acid sequence set forth in SEQ ID NOs: 23, 24, and 25, respectively;

(ii) the heavy chain CDR1, CDR2, and CDR3 comprises the amino acid sequences set forth in SEQ ID NOs: 14, 15, and 16, respectively, and the light chain CDR1, CDR2, and CDR3 comprises the amino acid sequences set forth in SEQ ID NOs: 26, 27, and 28, respectively;

(iii) the heavy chain CDR1, CDR2, and CDR3 comprises the amino acid sequences set forth in SEQ ID NOs: 17, 18, and 19, respectively, and the light chain CDR1, CDR2, and CDR3 comprises the amino acid sequences set forth in SEQ ID NOs: 29, 30, and 31, respectively; or

(iv) the heavy chain CDR1, CDR2, and CDR3 comprises the amino acid sequences set forth in SEQ ID NOs: 20, 21, and 22, respectively, and the light chain CDR1, CDR2, and CDR3 comprises the amino acid sequences set forth in SEQ ID NOs: 32, 33, and 34, respectively.

3 . The method of claim 1 , wherein the glaucoma is selected from the group consisting of an open-angle glaucoma, angle-closure glaucoma, normal-tension glaucoma (“NTG”), congenital glaucoma, secondary glaucoma, pigmentary glaucoma, pseudoexfoliative glaucoma, traumatic glaucoma, neovascular glaucoma, irido corneal endothelial syndrome, and uveitic glaucoma.

4 . The method of claim 1 , wherein the glaucoma is associated with an optic nerve damage, a retinal ganglion cell (“RGC”) loss, a high intraocular pressure (“IOP”), an impaired blood-retina barrier, and/or an increase in a level of microglia activity within a retina and/or optic nerve of the subject.

5 . The method of claim 1 , wherein the glaucoma is caused by a mechanical damage to an optic nerve head and/or an increase in a level of inflammation within a retina and/or an optic nerve of the subject.

6 . The method of claim 1 , wherein the anti-FAM19A5 antibody is capable of: (i) delaying an onset of retinal nerve cell degeneration within the subject; (ii) reducing a level of inflammation within the retina and/or optic nerve of the subject; (iii) increasing a frequency of or reducing the loss of retinal ganglion cells or restores the number of retinal ganglion cells within a ganglion cell layer of the retina of the subject; or (iv) any combinations thereof.

7 . The method of claim 1 , wherein the anti-FAM19A5 antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises an amino acid sequence which has at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 35, 36, 37, or 38; and wherein the VL comprises an amino acid sequence which has at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 39, 40, 41, or 42.

8 . The method of claim 1 , wherein the anti-FAM19A5 antibody is a chimeric antibody, a human antibody, or a humanized antibody.

9 . The method of claim 1 , wherein the FAM19A5 antibody of-the polynucleotide is administered intravitreally.

10 . The method of claim 1 , wherein the subject is a human.

11 . The method of claim 7 , wherein:

(i) the VH comprises the amino acid sequence set forth in SEQ ID NO: 35, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 39;

(ii) the VH comprises the amino acid sequence set forth in SEQ ID NO: 36, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 40;

(iii) the VH comprises the amino acid sequence set forth in SEQ ID NO: 37, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 41; or

(iv) the VH comprises the amino acid sequence set forth in SEQ ID NO: 38, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 42.

12 . The method of claim 2 , wherein the glaucoma:

(i) is selected from the group consisting of an open-angle glaucoma, angle-closure glaucoma, normal-tension glaucoma (“NTG”), congenital glaucoma, secondary glaucoma, pigmentary glaucoma, pseudoexfoliative glaucoma, traumatic glaucoma, neovascular glaucoma, irido corneal endothelial syndrome, and uveitic glaucoma;

(ii) is associated with an optic nerve damage, a retinal ganglion cell (“RGC”) loss, a high intraocular pressure (“IOP”), an impaired blood-retina barrier, and/or an increase in a level of microglia activity within a retina and/or optic nerve of the subject;

(iii) is caused by a mechanical damage to an optic nerve head and/or an increase in a level of inflammation within a retina and/or an optic nerve of the subject; or

(iv) any combination thereof.

13 . The method of claim 2 , wherein the anti-FAM19A5 antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises an amino acid sequence which has at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 35, 36, 37, or 38; and wherein the VL comprises an amino acid sequence which has at least about 80% sequence identity to the amino acid sequence set forth in SEQ ID NO: 39, 40, 41, or 42.

14 . The method of claim 13 , wherein:

(i) the VH comprises the amino acid sequence set forth in SEQ ID NO: 35, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 39;

(ii) the VH comprises the amino acid sequence set forth in SEQ ID NO: 36, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 40;

(iii) the VH comprises the amino acid sequence set forth in SEQ ID NO: 37, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 41; or

(iv) the VH comprises the amino acid sequence set forth in SEQ ID NO: 38, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 42.

15 . The method of claim 2 , wherein the anti-FAM19A5 antibody is a chimeric antibody, a human antibody, or a humanized antibody.

16 . The method of claim 2 , wherein the polynucleotide is administered intravitreally.

17 . The method of claim 1 , wherein the anti-FAM19A5 antibody is capable of specifically binding to the FAM19A5 epitope sequence VTLDRDSSQPRRTIARQT (SEQ ID NO: 201) or a fragment thereof.

18 . The method of claim 2 , wherein the anti-FAM19A5 antibody is capable of specifically binding to the FAM19A5 epitope sequence VTLDRDSSQPRRTIARQT (SEQ ID NO: 201) or a fragment thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2025
From: KIM, BONGCHEOL; KIM, DONG SIK; KWON, SOON-GU
To: NEURACLE SCIENCE CO., LTD.
Reel/Frame 070350/0897 →
Continuity (4)
Division 16626630
Provisional Application 62582889 · Nov 7, 2017
Provisional Application 62525639 · Jun 27, 2017
Related Publication 20240182555A1 · Jun 6, 2024
References Cited (104)
US 4044126A · Cook et al. · 1977 [cited by applicant]
US 4364923A · Cook et al. · 1982 [cited by applicant]
US 4414209A · Cook et al. · 1983 [cited by applicant]
US 5693780A · Newman et al. · 1997 [cited by applicant]
US 5709874A · Hanson et al. · 1998 [cited by applicant]
US 5759542A · Gurewich · 1998 [cited by applicant]
US 5840674A · Yatvin et al. · 1998 [cited by applicant]
US 5860957A · Jacobsen et al. · 1999 [cited by applicant]
US 5900252A · Calanchi et al. · 1999 [cited by applicant]
US 5948433A · Burton et al. · 1999 [cited by applicant]
US 5972366A · Haynes et al. · 1999 [cited by applicant]
US 5983134A · Ostrow · 1999 [cited by applicant]
US 5985307A · Hanson et al. · 1999 [cited by applicant]
US 5985317A · Venkateshwaran et al. · 1999 [cited by applicant]
US 6004534A · Langer et al. · 1999 [cited by applicant]
US 6010715A · Wick et al. · 2000 [cited by applicant]
US 6024975A · D'Angelo et al. · 2000 [cited by applicant]
US 6039975A · Shah et al. · 2000 [cited by applicant]
US 6048736A · Kosak · 2000 [cited by applicant]
US 6060082A · Chen et al. · 2000 [cited by applicant]
US 6071495A · Unger et al. · 2000 [cited by applicant]
US 6120751A · Unger · 2000 [cited by applicant]
US 6131570A · Schuster et al. · 2000 [cited by applicant]
US 6139865A · Friend et al. · 2000 [cited by applicant]
US 6167301A · Flower et al. · 2000 [cited by applicant]
US 6253872B1 · Neumann · 2001 [cited by applicant]
US 6256533B1 · Yuzhakov et al. · 2001 [cited by applicant]
US 6261595B1 · Stanley et al. · 2001 [cited by applicant]
US 6267983B1 · Fujii et al. · 2001 [cited by applicant]
US 6271359B1 · Norris et al. · 2001 [cited by applicant]
US 6274552B1 · Tamarkin et al. · 2001 [cited by applicant]
US 6316652B1 · Steliou · 2001 [cited by applicant]
US 9579398B2 · Seong et al. · 2017 [cited by applicant]
US 10640557B2 · Seong et al. · 2020 [cited by applicant]
US 11155613B2 · Kim et al. · 2021 [cited by applicant]
US 11332521B2 · Kim et al. · 2022 [cited by applicant]
US 11560425B2 · Kim et al. · 2023 [cited by applicant]
US 11746149B2 · Kim et al. · 2023 [cited by applicant]
US 20040014194A1 · Beyer et al. · 2004 [cited by applicant]
US 20090221670A1 · Borglum et al. · 2009 [cited by applicant]
US 20120100140A1 · Reyes et al. · 2012 [cited by applicant]
US 20160060705A1 · O'Donnell et al. · 2016 [cited by applicant]
US 20200299373A1 · Kim et al. · 2020 [cited by applicant]
EP 2815769A1 · 2014 [cited by applicant]
KR 20160101786A · 2016 [cited by applicant]
WO WO9712622A1 · 1997 [cited by applicant]
WO WO9817815A1 · 1998 [cited by applicant]
WO WO9817816A1 · 1998 [cited by applicant]
WO WO9818934A1 · 1998 [cited by applicant]
WO WO9931251A1 · 1999 [cited by applicant]
WO WO2015015000A1 · 2015 [cited by applicant]
WO WO2019003162A1 · 2019 [cited by applicant]
WO WO2019215702A1 · 2019 [cited by applicant]
An, Z., et al., “IgG2m4, an Engineered Antibody Isotype with Reduced Fc Function,” Mabs 1(6):572-579, Taylor & Francis, United States (Nov.-Dec. 2009). [cited by applicant]
Ashwell, K.W., et al., “The Appearance and Distribution of Microglia in the Developing Retina of the Rat,” Visual Neuroscience 2(5):437-448, Cambridge University Press, United Kingdom (May 1989). [cited by applicant]
Bird, R.E., et al., “Single-chain Antigen-binding Proteins,” Science 242(4877):423-426, Association for the Advancement of Science, United States (Oct. 1988). [cited by applicant]
Bosco, A., et al., “Early Microglia Activation in a Mouse Model of Chronic Glaucoma,” The Journal of Comparative Neurology 519(4):599-620, Wiley-Liss, United States (Mar. 2011). [cited by applicant]
Bricogne, G., “Bayesian Statistical Viewpoint on Structure Determination: Basic Concepts and Examples,” Methods in Enzymology 276:361-423, Academic Press, United States (Jan. 1997). [cited by applicant]
Bricogne, G., “Direct Phase Determination by Entropy Maximization and Likelihood Ranking: Status Report and Perspectives,” Acta Crystallographica. Section D, Biological Crystallography 49(Pt1):37-60, Wiley-Blackwell, Un… [cited by applicant]
Champe, M., et al., “Monoclonal Antibodies that Block the Activity of Leukocyte Function-Associated Antigen 1 Recognize Three Discrete Epitopes in the Inserted Domain of CD11a,” The Journal of Biological Chemistry 270 (… [cited by applicant]
Chayen, N.E., et al., “The Role of Oil in Macromolecular Crystallization,” Structure 5(10):1269-1274, Cell Press, United States (Oct. 1997). [cited by applicant]
Cheung, R.C., et al., “Epitope-specific Antibody Response to the Surface Antigen of Duck Hepatitis B Virus in Infected Ducks,” Virology 176(2):546-552, Academic Press, United States (Jun. 1990). [cited by applicant]
Chothia, C. and Lesk, A.M., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” Journal of Molecular Biology 196(4):901-917, Elsevier Science, United States (Aug. 1987). [cited by applicant]
Cunningham, B.C. and Wells, J.A., “High-resolution Epitope Mapping of hGH-receptor Interactions by Alanine-scanning Mutagenesis,” Science 244(4908):1081-1085, American Association for the Advancement of Science, United … [cited by applicant]
Edelman, G.M. et al., “The Covalent Structure of an Entire gammaG Immunoglobulin Molecule,” Proceedings of the National Academy of Sciences USA 63(1):78-85, National Academy of Sciences, United States (May 1969). [cited by applicant]
Gieger, R., et al., “Crystallogenesis of Biological Macromolecules: Facts and Perspectives,” Acta Crystallographica. Section D, Biological Crystallography 50(Pt4):339-350, Wiley- Blackwell, United States (Jul. 1994). [cited by applicant]
Gupta, D. and Chen P.P., “Glaucoma,” American Family Physician 93(8):668-674, American Academy of General Practice, United States (Apr. 2016). [cited by applicant]
Harasymowycz, P., et al., “Medical Management of Glaucoma in the 21st Century from a Canadian Perspective,” Journal of Ophthalmology 2016:6509809, Hindawi Publishing Corporation, United States (Nov. 2016). [cited by applicant]
Harmsen, M.M., et al., “Properties, Production, and Applications of Camelid Single-Domain Antibody Fragments, ” Applied Microbiology and Biotechnology 77(1):13-22, Springer International, Germany (Nov. 2007). [cited by applicant]
Huston, J.S., et al., “Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-digoxin Single-chain Fv Analogue Produced in Escherichia Coli,” Proceedings of the National Academy of Scien… [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2018/054782, European Patent Office, Rijswijk, mailed on Nov. 16, 2018, 12 pages. [cited by applicant]
Jefferis, R., et al., “Human Immunoglobulin Allotypes: Possible Implications for Immunogenicity,” Mabs 1(4):332-338, Taylor & Francis, United States (Jul.-Aug. 2009). [cited by applicant]
Kabat, E.A. and Wu, T.T., “Attempts to Locate Complementarity-Determining Residues in the Variable Positions of Light and Heavy Chains,” Annals of the New York Academy of Sciences 190:382-393, Blackwell, United States (… [cited by applicant]
Kettenmann, H, et al., “Physiology of Microglia,” Physiological Reviews 91(2):461-553, American Physiological Society, United States (Apr. 2011). [cited by applicant]
Kirkland, T.N., et al., “Analysis of the Fine Specificity and Cross-reactivity of Monoclonal Anti-lipid A Antibodies,” Journal of Microbiology 137(11):3614-3619, Microbiological Society of Korea, Korea (Dec. 1986). [cited by applicant]
Kostelny, S.A., et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers,” The Journal of Immunology 148(5):1547-1553, American Association of Immunologists, United States (Mar. 1992). [cited by applicant]
Lau, C., et al., “Chimeric Anti-CD14 IGG2/4 Hybrid Antibodies for Therapeutic Intervention in Pig and Human Models of Inflammation,” Journal of Immunology 91(9):4769-4777, American Association of Immunologists, United S… [cited by applicant]
Lee, B.L., et al., “The Glaucoma Symptom Scale. A Brief Index of Glaucoma-Specific Symptoms,” Archives of Ophthalmology 116(7):861-866, American Medical Association, United States (Jul. 1998). [cited by applicant]
Lefranc, M.P., et al., “IMGT Unique Numbering for Immunoglobulin and T Cell Receptor Variable Domains and Ig Superfamily V-like Domains,” Developmental and Comparative Immunology 27(1):55-77, Elsevier Science, United St… [cited by applicant]
Lonberg, N., “Human Antibodies From Transgenic Animals,” Nature Biotechnology, 23(9):1117-1125, Nature America Publishing, United States (Sep. 2005). [cited by applicant]
McCafferty, J., et al., “Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains,” Nature 348(6301):552-554, Nature Publishing Group, United Kingdom (Dec. 1990). [cited by applicant]
McPherson, A., “Crystallization of Proteins From Polyethylene Glycol,” The Journal of Biological Chemistry 251(20):6300-6303, American Society for Biochemistry and Molecular Biology, United States (Oct. 1976). [cited by applicant]
McPherson, A., “Current Approaches to Macromolecular Crystallization,” European Journal of Biochemistry 189(1):1-23, Blackwell Science Ltd, United Kingdom (Apr. 1990). [cited by applicant]
Moldenhauer, G., et al., “Identity of HML-1 Antigen on Intestinal Intraepithelial T Cells and of B-ly7 Antigen on Hairy Cell Leukaemia,” Scandinavian Journal of Immunology 32(2):77-82, Blackwell Scientific Publications,… [cited by applicant]
Morel, G.A., et al., “Monoclonal Antibodies to Bovine Serum Albumin: Affinity and Specificity Determinations,” Molecular Immunology 25(1):7-15, Pergamon Press, United Kingdom (Jan. 1988). [cited by applicant]
Morris, G.E., “Epitope Mapping by Chemical Fragmentation,” Methods in Molecular Biology 66:121-127, Humana Press, United States (Jan. 1996). [cited by applicant]
Ram, J. and Agarwal, A., “The Challenge of Childhood Cataract Blindness,” The Indian Journal of Medical Research 140(4):472-474, Medknow, India (Oct. 2014). [cited by applicant]
Roux, K.H., et al., “Comparisons of the Ability of Human IgG3 Hinge Mutants, IgM, IgE, and IgA2, to form Small Immune Complexes: A Role for Flexibility and Geometry,” The Journal of Immunology 161(8):4083-4090, American… [cited by applicant]
Roversi, P., et al., “Modelling Prior Distributions of Atoms for Macromolecular Refinement and Completion,” Acta Crystallographica. Section D, Biological Crystallography 56(Pt10):1316-1323, International Union of Crysta… [cited by applicant]
Sanes, J.R., et al., “The Types of Retinal Ganglion Cells: Current Status and Implications for Neuronal Classification,” Annual Review of Neuroscience 38:221-246, Annual Reviews, inc., United States (Jul. 2015). [cited by applicant]
Sommer, A., et al., “Relationship Between Intraocular Pressure and Primary Open Angle Glaucoma Among White and Black Americans. The Baltimore Eye Survey,” Archives of Ophthalmology 109(8): 1090-1095, American Medical As… [cited by applicant]
Songsivilai, S. and Lachmann, P.J., “Bispecific Antibody: A Tool for Diagnosis and Treatment of Disease,” Clinical and Experimental Immunology 79(3):315-321, Blackwell Scientific Publications, United Kingdom (Mar. 1990). [cited by applicant]
Stahli, C., et al., “Distinction of Epitopes by Monoclonal Antibodies,” Methods in Enzymology 92:242-253, Academic Press, United States (Jan. 1983). [cited by applicant]
Tang, T.Y., et al., “TAFA: A Novel Secreted Family With Conserved Cysteine Residues and Restricted Expression in the Brain,” Genomics 83(4):727-734, Academic Press, United States (Apr. 2004). [cited by applicant]
Tezel, G., et al., “TNF-Alpha and TNF-Alpha Receptor-1 in the Retina of Normal and Glaucomatous Eyes,” Investigative Ophthalmology & Visual Science 42(8):1787-1794, Association For Research In Vision And Ophthalmology, … [cited by applicant]
Vidarsson, G., et al., “IgG Subclasses and Allotypes: from Structure to Effector Functions,” Frontiers in Immunology 5(Article 520): 17 pages, Lausanne : Frontiers Research Foundation, Switzerland (Oct. 2014). [cited by applicant]
Vohra, R., et al., “The Role of Inflammation in the Pathogenesis of Glaucoma,” Survey of Ophthalmology 58(4):311-320, Elsevier Science, United States (Jul.-Aug. 2013). [cited by applicant]
Wang, W.H., et al., “Increased Expression of Serum Amyloid a in Glaucoma and Its Effect on Intraocular Pressure,” Investigative Ophthalmology & Visual Science 49(5):1916-1923, Association For Research In Vision And Opht… [cited by applicant]
Ward, E.S., et al., “Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from Escherichia Coli,” Nature 341(6242):544-546, Nature Publishing Group, United Kingdom (Oct. 1989). [cited by applicant]
Wilsey, L.J. and Fortune, B., “Electroretinography in Glaucoma Diagnosis,” Current Opinion in Ophthalmology 27(2):118-124, Lippincott Williams & Wilkins, United States (Mar. 2016). [cited by applicant]
Busby, M., et al., “Systematic comparison of monoclonal versus polyclonal antibodies for mapping histone modifications by ChIP-seq,” Biorxiv, pp. 1-26, Cold Spring Harbor Laboratory, United States (May 2016). [cited by applicant]
Pennington, K.L., et al., “Epigenetic Mechanisms of the Aging Human Retina,” J Exp Neurosci 9(Suppl 2):51-79, ICI Journals, United States (Feb. 2016). [cited by applicant]
Co-pending, U.S. Appl. No. 19/029,984, inventors Kim, B., et al., filed Jan. 17, 2025 (Not yet Published). [cited by applicant]
UniProt, “TAFA5_HUMAN,” Accession No. Q7Z5A7, accessed at https://www.uniprot.org/uniprotkb/Q7Z5A7/entry#Q7Z5A7-1, accessed on Apr. 28, 2025, 7 pages. [cited by applicant]